Loading...
Bilateral Trade Intelligence · $14 Total Trade · 1 Foreign Suppliers · 1 Indian Buyers · DGFT Verified · Updated March 2026
India imported $14 worth of pharmaceutical formulations from Gabon across 1 verified shipments, from 1 foreign suppliers to 1 Indian buyers. The top suppliers are CENTRE DE RECHERCHES DE MEDICALES DE LAMBARENE ($14). The leading products are Plasma ($14). Average shipment value: $14.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Plasma | $14 | 100.0% |
India imports 1+ pharmaceutical formulations from Gabon with a combined trade value of $14. Key products include Plasma ($14). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 1 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Gabon, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Gabon buyers, regulatory requirements, and logistics for that specific product corridor. Products include Plasma ($14) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
1 Indian pharmaceutical companies export finished formulations to Gabon. Leading exporters include Centre De Recherches De Medicales De Lambarene, . The top exporter accounts for 100.0% of total India–Gabon pharma exports. Source: Indian Customs (DGFT).
1 companies in Gabon import pharmaceutical formulations from India. Top buyers include Zydus Lifesciences Limited, . The largest buyer accounts for 100.0% of India–Gabon pharma imports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Gabon and India has remained relatively underdeveloped from 2022 to 2026. In 2022, India imported a total of $14 worth of pharmaceutical products from Gabon, comprising a single shipment of plasma. This minimal trade volume indicates limited engagement between the two nations in the pharmaceutical sector during this period. The lack of significant growth or diversification in product categories suggests that the trade relationship has not evolved substantially over the past few years.
Gabon has played an insignificant role in India's pharmaceutical import landscape. The total import value from Gabon accounted for a mere fraction of India's overall pharmaceutical imports, highlighting Gabon's minimal share in the market. The sole product imported, plasma, underscores the limited scope of pharmaceutical categories traded between the two countries.
Between 2024 and 2026, there have been no notable developments or policy changes by the Central Drugs Standard Control Organisation (CDSCO) specifically affecting pharmaceutical imports from Gabon. The trade relationship has remained static, with no new trade agreements or regulatory harmonization efforts targeting this corridor.
Registration process, GMP requirements, import documentation
For Gabonese pharmaceutical companies to register their products for import into India, they must comply with the CDSCO's stringent requirements. This includes obtaining an import license under Form 10 of the Drugs and Cosmetics Rules, 1945, and registering the product under Form 41. The process involves submitting comprehensive documentation, including a Certificate of Pharmaceutical Product (COPP) and a Certificate of Analysis (CoA) for each batch. Clinical trial data may be required, depending on the product's nature and classification. The timeline for approval can vary, often taking several months, depending on the completeness and accuracy of the submitted documentation.
India mandates that all imported pharmaceutical products adhere to Good Manufacturing Practice (GMP) standards as prescribed by the CDSCO. Manufacturing facilities in Gabon must be compliant with these standards, which may include obtaining WHO prequalification. The CDSCO conducts inspections to verify compliance, and any discrepancies can lead to delays or rejections of import applications.
Importing pharmaceutical products into India requires several key documents:
Additionally, compliance with customs procedures, including proper labeling and packaging, is essential for smooth clearance.
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical imports from Gabon to India have been limited to a single product category: plasma. This singular focus indicates a lack of diversification in the types of pharmaceutical products traded between the two countries. There is no evidence of imports of patented drugs, biologics, or specialty products from Gabon to India during this period.
Given the minimal trade volume and product diversity, there is no indication that India imports innovator drugs, novel formulations, or advanced therapies from Gabon. The trade relationship has not facilitated the exchange of specialized pharmaceutical products not manufactured domestically in India.
The negligible import volume from Gabon suggests that factors such as patent protection, technology gaps, or disease burden have not driven India to source pharmaceutical products from Gabon. The limited trade indicates that Gabonese pharmaceutical products do not fulfill specific needs or demands within the Indian market.
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes the Most Favored Nation (MFN) tariff rates, basic customs duty, Integrated Goods and Services Tax (IGST), and health cess. However, due to the minimal import volume from Gabon, these tariffs have not significantly impacted the trade dynamics between the two countries.
There are no existing Free Trade Agreements (FTAs) or preferential duty rates between India and Gabon that influence pharmaceutical imports. The lack of such agreements has contributed to the stagnant trade relationship in the pharmaceutical sector.
India's patent regime, including Section 3(d) and provisions for compulsory licensing, does not appear to have influenced pharmaceutical imports from Gabon. The National Pharmaceutical Pricing Authority (NPPA) exercises price control on imported drugs; however, the minimal import volume from Gabon suggests that these regulations have had little to no effect on the trade dynamics.
Shipping routes, port infrastructure, cold chain compliance
The pharmaceutical trade between Gabon and India has been limited to a single shipment of plasma, indicating that established sea and air routes are underutilized for this trade corridor. The lack of consistent trade has resulted in minimal data on transit times and route reliability.
The key export port in Gabon for pharmaceutical products is the Port of Libreville. In India, pharmaceutical imports are typically handled by major ports such as Mumbai, Chennai, and Kolkata. However, due to the minimal trade volume from Gabon, these ports have not been significantly engaged in handling Gabonese pharmaceutical shipments.
The Indian customs clearance process for pharmaceutical imports involves compliance with CDSCO testing, cold chain requirements, and Good Distribution Practice (GDP) standards. However, the limited import volume from Gabon suggests that these procedures have not been extensively applied to Gabonese pharmaceutical products.
Market size, healthcare system, growth outlook
India's minimal import of pharmaceutical products from Gabon indicates that the country does not rely on Gabon for specific pharmaceutical needs. The domestic pharmaceutical industry in India is robust, reducing the necessity to import from Gabon.
There is no significant presence of Gabonese pharmaceutical companies supplying products to India. The lack of trade volume suggests that Gabonese companies have not established partnerships or engaged in contract manufacturing within the Indian market.
India's "Atmanirbhar Bharat" initiative and the Production-Linked Incentive (PLI) scheme aim to bolster domestic pharmaceutical manufacturing. These efforts are likely to further reduce the need for pharmaceutical imports from Gabon, potentially leading to a decline or stagnation in trade between the two countries.
Competing origins, India's edge, challenges and threats
India imports pharmaceutical products from various countries, including the USA, EU, China, Switzerland, and Japan. Gabon's share in this competitive landscape is negligible, with other origins dominating the Indian pharmaceutical import market.
The limited trade volume suggests that Gabonese pharmaceutical products do not offer distinct advantages such as innovation, quality, patent protection, or brand reputation that would attract Indian buyers.
The Indian pharmaceutical industry is developing alternatives to imported products through biosimilars, process patents, and capacity expansion under the PLI scheme. These domestic advancements further diminish the potential for imports from Gabon, as India increasingly relies on its own manufacturing capabilities.
India exported pharmaceuticals worth $14 to Gabon across 1 verified shipments.
1. CENTRE DE RECHERCHES DE MEDICALES DE LAMBARENE — $14. Total: 1 suppliers.
1. ZYDUS LIFESCIENCES LIMITED — $14. 1 buyers total.
1. Plasma ($14, 100.0%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $14 corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$14 per consignment across 1 shipments.
1 Indian companies. Largest: CENTRE DE RECHERCHES DE MEDICALES DE LAMBARENE with $14.
TransData Nexus covers 1 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 1 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Exporters
1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists